Blueprint Medicines Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Blueprint Medicines Corporation
ADAURA Survival Boost For AZ’s Tagrisso
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a Pink Sheet analysis of FDA approval decisions since 2021.
Blueprint Sees Blockbuster Potential For Ayvakit In Systemic Mastocytosis With ISM Nod
The US FDA gave the drug a broad label in adults with indolent SM, without restrictions for disease severity or prior treatment, and Blueprint sees a potential $1.5bn market opportunity.
Keeping Track: Showers Of Approvals In US FDA’s May Forecast
Upcoming user fees include 16 novel agents, featuring two RSV vaccines, two gene therapies, and three oncologics. The Pink Sheet’s US FDA Performance Tracker breaks down the big month to come.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Hoyle Pharmaceuticals, Inc.
- ImmunoCo, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.